AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02180243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation/Acupuncture
Description: Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
Study NCT02180243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gulf War Health Education
Description: Participants randomized to this group will take part in a health education group.
Study NCT02459002 — intervention group
Intervention type: BEHAVIORAL
Intervention: QOL Questionnaire
Description: Participant outcomes assessed with survey
Study NCT02459002 — intervention group
Intervention type: BEHAVIORAL
Intervention: Caregiver Satisfaction Questionnaire
Description: Caregiver satisfaction with quality of care assessed with surveys
Study NCT02228759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
Study NCT03369171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)
Description: MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2).
Study NCT00972660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC)
Description: Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
Study NCT00972660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone and cyclosporine or primary therapies
Description: Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)
Study NCT01305239 — intervention group
Intervention type: DRUG
Intervention: Aromasin
Description: Aromasin 25 mg daily.
Study NCT00556465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg of effervescent N-acetylcysteine tablet twice per day for three months
Study NCT01638143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MenaQ7 M-1500 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Study NCT01638143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gnosis P-1000 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Study NCT01638143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gnosis M-1500 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Study NCT00044798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Participants will receive 15 treatments of rTMS over 3 weeks.
Study NCT00044798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
Study NCT00044798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
Study NCT00044798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Participants will receive 15 treatments of sham rTMS over 3 weeks.
Study NCT00743977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine HCl
Description: 100mg tablet in fasting state
Study NCT00743977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine HCl
Description: 100mg tablet in fasting state
Study NCT02163005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: -agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
Study NCT02630589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory brainstem implant
Description: The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
Study NCT03501602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA protector
Description: In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
Study NCT03501602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel LMA
Description: In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
Study NCT01383564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP group
Description: Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
Study NCT01383564 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non CPAP group
Description: Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
Study NCT04671966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
Study NCT04671966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide
Description: Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
Study NCT04671966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
Study NCT04671966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure
Description: This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
Study NCT01593475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by CCRT
Description: Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively.
Study NCT04235153 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the 9 dimensions of the CANUT-QVA questionnaire
Description: Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~1. Making food~2. Place where the meals are eaten~3. Eating and drinking: Nutrition~4. Eating and drinking: The pleasure of tasting, chewing~5. Eating and drinking: Satiated, well being~6. Food preparation: Supply, choice, presentation~7. Eating and drinking: Feelings~8. After eating: heaviness, discomfort, hunger~9. Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions.
Study NCT04408703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Red Density
Description: Image analysis of endoscopic images in patients with ulcerative colitis
Study NCT04276753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Terminalia Chebula Fruit Extract
Description: Standardized fruit extract
Study NCT04276753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03101839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4785
Description: KRAS Antisense Oligonucleotide
Study NCT02167009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
Study NCT02751268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
Study NCT02751268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
Study NCT00506441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
Study NCT00506441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Study NCT03656172 — intervention group
Intervention type: BIOLOGICAL
Intervention: Haemoglobin measure
Description: Haemoglobin measure before and one month after standard iron treatment
Study NCT03977181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Community Health Club
Description: GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
Study NCT03977181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-based Adherence Support
Description: IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
Study NCT02506075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranical direct current stimulator
Description: approved by Conformity European as safe treatment device for stroke patients
Study NCT02506075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual inattention training
Study NCT01192321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric T3 - T9
Description: Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
Study NCT01192321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal
Description: Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
Study NCT02979964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Study NCT02187783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
Study NCT02262780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan
Study NCT02262780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan
Study NCT02262780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Study NCT02697071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Study NCT02697071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Study NCT02163161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
Study NCT02163161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
Study NCT02163161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF- 04965842
Description: Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
Study NCT01690663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.25%
Study NCT01690663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Study NCT01690663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01690663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo
Study NCT04263259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: Mobile-Delivered Cognitive Retraining Intervention
Study NCT02844166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: viscoelastic surface support
Description: Patients will be placed in an ICU bed with viscoelastic surface support
Study NCT02844166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pyramidal foam surface support
Description: Patients will be placed in an ICU bed with pyramidal foam surface support
Study NCT01133548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel 1.62%
Description: 5 grams administered using an application Site Rotation
Study NCT01133548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel 1.62%
Description: 5 grams administered using an a combination of Application sites
Study NCT03087864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg i.v. day 1-22-43-64-85
Study NCT03087864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT03087864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT03087864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy
Study NCT04541355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04541355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing Handicap Inventory for Adults - Screening
Description: Patient self-assessment questionnaire to measure probability of hearing impairment
Study NCT04541355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered according to the standard of care
Study NCT04541355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study NCT00269152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
Study NCT00269152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
Study NCT00269152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
Study NCT03518567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked marijuana cigarettes: High THC dose (6% THC)
Description: Smoked marijuana cigarettes (High THC dose \[6% THC\])